Qiagen NV | QIA - Selling And Administration Expenses


Qiagen NV reported $142.33M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
argenx SE USD 417M 62M Jun/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Moderna USD 216M 43M Jun/2026
Organon & Co USD 434M 10M Jun/2026
Qiagen NV USD 142.33M 60K Jun/2026
Revvity USD 278.58M 24.69M Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Viatris USD 1.13B 205.7M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026